Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

PHASE4CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

February 16, 2024

Study Completion Date

July 29, 2025

Conditions
Haploidentical Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Individual Antithymocyte globulin

Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.

DRUG

Antithymocyte globulin

A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Peking University People's Hospital, Peking University Institute of Hematology

UNKNOWN

collaborator

Department of Hematology, The First Affiliated Hospital of Zhengzhou University

UNKNOWN

lead

Chinese PLA General Hospital

OTHER

NCT05166967 - Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter